Amount of analgesia · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Viral isolates · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)
1 finding from 1 review
Orlowski 2004: 182 throat swabs performed for patients receiving 500 mg of valaciclovir (n = 40) and 198 swabs for those receiving 1000 mg (n = 41); all of the cultures proved negative (1 trial, 81; not estimable).
1 study · 81 participants
GRADE not reported
Presence/absence of HSV oral lesions · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) showed no clear difference in presence/absence of HSV oral lesions compared with prophylactic valaciclovir (oral); GRADE not reported.
1 finding from 1 review
Presence/absence of HSV oral lesions · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) led to lower presence/absence of HSV oral lesions compared with placebo; GRADE not reported.
1 finding from 1 review
Length of hospital stay · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
Patient quality of life · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Recurrence of lesions · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)
1 finding from 1 review
One study reported adverse effects (Warkentin 2002). Twenty patients allocated to receive high dose valaciclovir reported adverse effects (42%); for the low dose group this number was 27 (52%). Adverse effects were…
1 study · 100 participants
GRADE not reported
Cost of oral care · Patients being treated for cancer (predominantly haematological malignancies)
1 finding from 1 review
Only one trial reported on the cost of prophylaxis for HSV (Liesveld 2002). The reported mean pharmacy costs for those randomised to receive aciclovir were $1080 compared to $320 for those initially randomised to…
1 study · 30 participants
GRADE not reported
Adverse effects · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review
Cost of oral care · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Viral isolates · Patients being treated for cancer (leukaemia)
Prophylactic prostaglandin E (oral) led to higher viral isolates compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse effects · Patients being treated for cancer (predominantly haematological malignancies)
1 finding from 1 review
Quality of life (validated questionnaire) · Children or adolescents aged 3 years or older with velopharyngeal insufficiency (VPI) associated with non-syndromic submucous cleft palate
The review found no eligible studies for this question.
1 finding from 1 review
Instrumental assessment: nasalance score (nasometry and pressure-flow measure) · Children or adolescents aged 3 years or older with velopharyngeal insufficiency (VPI) associated with non-syndromic submucous cleft palate
The review found no eligible studies for this question.
1 finding from 1 review
Self-esteem (Piers-Harris self-concept scale) · Children or adolescents aged 3 years or older with velopharyngeal insufficiency (VPI) associated with non-syndromic submucous cleft palate
The review found no eligible studies for this question.
1 finding from 1 review
Instrumental assessment: velopharyngeal complete closure and gap size (videonasopharyngoscopy and multiview videofluoroscopy) · Children or adolescents aged 3 years or older with velopharyngeal insufficiency (VPI) associated with non-syndromic submucous cleft palate
1 finding from 1 review
Complete closure occurred in 32 (86%) of the participants in group 1 (MIPP) and in 31 (89%) in group 2, P > 0.05. After eliminating the nine patients with residual velopharyngeal insufficiency, the post-operative gap…
1 study · 72 participants
GRADE not reported
Adverse effect: failure of muscle fusion in the region of the cleft after surgery · Children or adolescents aged 3 years or older with velopharyngeal insufficiency (VPI) associated with non-syndromic submucous cleft palate
1 finding from 1 review
Adverse effect: unacceptable nasal resonance after repair · Children or adolescents aged 3 years or older with velopharyngeal insufficiency (VPI) associated with non-syndromic submucous cleft palate
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effect: obstructive sleep apnoea or airway compromise · Children or adolescents aged 3 years or older with velopharyngeal insufficiency (VPI) associated with non-syndromic submucous cleft palate
1 finding from 1 review